Artesunate injection is a semi-synthetic water-soluble derivative of artemisinin. Recommended by the WHO and drug regulatory authorities worldwide as a first-line therapeutic agent for severe malaria, it features rapid onset, high safety and low drug resistance, and is widely used in emergency treatment of severe Plasmodium falciparum infections in adults and children. With advances in pharmacological research technologies, the academic community has moved beyond its sole anti-malarial profile.
Accumulating evidence reveals that the product exerts multiple pharmacological activities including anti-inflammation, anti-tumor, anti-fibrosis and immune regulation. Characterized by unique multi-pathway and multi-target effects, it has become a research hotspot in drug repurposing, offering novel research directions and application potential for treating refractory diseases such as tumors, autoimmune disorders and organ injuries.
our Products form
Artesunate COA
Non-Antimalarial Pharmacological Mechanisms (Core Expansion for Drug Repurposing)
Regulatory Mechanism of Oxidative Stress and Programmed Cell Death Network
Imbalanced oxidative stress and disrupted programmed cell death constitute the core pathological basis of tumorigenesis, organ injury and inflammatory lesions. Artesunate injection exerts bidirectional biological effects through multi-dimensional modulation of oxidative stress levels and intervention in diverse programmed cell death pathways, with pronounced cell- and tissue-dependent properties - this serves as the core molecular foundation supporting its repurposing.In contrast, in damaged normal tissue cells, it moderately modulates oxidative stress, attenuates excessive apoptosis and elicits organ-protective effects.
Such bidirectional effects precisely match the pathological requirements of different diseases.In general, in abnormally proliferating and lesioned tumor cells, artesunate mainly induces oxidative stress and activates programmed cell death cascades to suppress cell proliferation and facilitate apoptosis.Ferroptosis represents the most vigorously investigated direction in non-antimalarial research of artesunate, and also serves as a universal core pathway underlying its anti-tumor and organ-protective functions. Ferroptosis is a novel form of programmed cell death reliant on iron overload and accumulation of lipid peroxidation, distinct from classical apoptosis and pyroptosis pathways.
Artesunate activates ferroptosis via multiple mechanisms. On one hand, it markedly elevates the labile iron pool in cells and disrupts iron homeostasis; excess free iron generates abundant reactive oxygen species (ROS) through the Fenton reaction, aggravating oxidative damage. On the other hand, it specifically inhibits the expression and activity of GPX4, a key regulatory protein of ferroptosis, blocking the clearance pathway of cellular lipid peroxides and resulting in massive accumulation of lipid peroxidation products, ultimately triggering ferroptosis in target cells. This mechanism has been widely validated in various tumor cell lines including hepatocellular carcinoma, lung cancer and breast cancer, effectively restraining tumor proliferation, invasion and metastasis.
Meanwhile, in myocardial, renal, hepatic and other organ ischemia-reperfusion injury models, artesunate moderately regulates ferroptosis to curb excessive ferroptosis in normal cells, alleviate oxidative organ damage and confer protective effects.
Beyond ferroptosis, artesunate concurrently modulates multiple canonical programmed cell death pathways to form a synergistic regulatory network. In the mitochondrial apoptotic pathway, artesunate upregulates pro-apoptotic Bax and downregulates anti-apoptotic Bcl-2, impairs mitochondrial membrane integrity, promotes cytochrome C release, activates the caspase cascade and induces mitochondrial-dependent apoptosis in tumor cells.
Mild short-term stress facilitates cellular damage repair, whereas sustained intense stress triggers tumor cell apoptosis, enabling specific elimination of lesioned cells. For pyroptosis regulation, artesunate suppresses activation of pivotal pyroptotic proteins, reduces release of inflammatory factors and mitigates tissue injury mediated by excessive inflammation. Furthermore, artesunate modulates autophagy and ferritinophagy. It mediates ferritin degradation to liberate free iron and further amplify ferroptotic effects; meanwhile, moderate activation of autophagy in normal cells eliminates damaged organelles and oxidative products, alleviates oxidative stress injury and completes its bidirectionally regulated pharmacological system.
Mechanisms of Inflammatory and Innate Immune Regulatory Pathways
Chronic inflammation and aberrant activation of innate immunity are primary triggers for sepsis, autoimmune diseases and chronic organ damage. Artesunate injection bidirectionally regulates inflammatory responses and remodels innate immune homeostasis by inhibiting pro-inflammatory pathways and activating antioxidant pathways, which constitutes its core mechanism for treating inflammatory disorders. Its major action targets are concentrated on canonical inflammatory signaling cascades and antioxidant pathways, enabling inhibition of inflammatory cascade amplification at the source and alleviation of tissue inflammatory infiltration and injury.
In terms of pro-inflammatory pathway suppression, artesunate precisely blocks three core inflammatory axes: NF-κB, TLR4/MyD88 and the NLRP3 inflammasome. As a master transcription factor governing inflammation, NF-κB resides in the cytoplasm under resting conditions; upon abnormal activation, it translocates into the nucleus to initiate transcription of numerous pro-inflammatory genes. Artesunate inhibits NF-κB nuclear translocation and phosphorylation, interrupts inflammatory signal transduction and suppresses inflammation initiation at the root. The TLR4/MyD88 pathway acts as a core sensor for pathogen- and damage-associated signals.
The drug downregulates expression of TLR4 and MyD88 proteins, inhibits downstream activation of inflammatory signal cascades and reduces inflammatory responses induced by exogenous and endogenous insults. The NLRP3 inflammasome functions as a critical hub for inflammatory amplification. Artesunate impedes NLRP3 inflammasome assembly and activation, blocking caspase-1-mediated maturation and secretion of downstream inflammatory cytokines. Through regulation of the above pathways, artesunate significantly reduces serum and tissue levels of key pro-inflammatory factors including TNF-α, IL-1β and IL-6, effectively relieving acute inflammatory storms and persistent chronic inflammation.
For antioxidant pathway activation, artesunate specifically triggers the Nrf2/HO-1 antioxidant cascade to exert anti-oxidative and anti-damaging effects. Nrf2 is the central transcription factor for countering oxidative stress, governing the expression of antioxidant proteins such as HO-1, SOD and GSH. Artesunate facilitates Nrf2 nuclear translocation, elevates activity of HO-1 antioxidant enzymes, eliminates excess intracellular ROS and attenuates oxidative stress-mediated tissue injury. It also suppresses secondary inflammation provoked by oxidative stress, establishing a virtuous cycle of "anti-oxidation and anti-inflammation".
This mechanism has been verified in models of sepsis-induced organ injury, lung injury, hepatic injury and autoimmune inflammation, providing important theoretical support for the management of inflammatory diseases.
Adaptive Immunity Remodeling Mechanisms
Dysregulated adaptive immunity is a key mechanism underlying tumor immune suppression and the pathogenesis of autoimmune diseases. By reshaping the balance of adaptive immune cells and modulating the tumor immune microenvironment, artesunate achieves bidirectional regulation of immune function and exhibits great value in anti-tumor immunotherapy and intervention against autoimmune disorders.
Its effects cover multiple core links including T cell subset balance, macrophage polarization and immune checkpoint modulation, restoring immune homeostasis from multiple dimensions.
The Treg/Th17 balance serves as a hallmark of adaptive immune homeostasis. Treg cells primarily mediate immune suppression, while Th17 cells drive inflammatory immune responses. Imbalance between the two represents a prominent pathological feature of autoimmune diseases such as rheumatoid arthritis and Sjögren's syndrome.
By regulating key transcription factors including STAT3 and Foxp3, artesunate inhibits abnormal proliferation and differentiation of Th17 cells, decreases secretion of pro-inflammatory cytokines such as IL-17, and moderately enhances Treg cell function. It restores Treg/Th17 immune equilibrium, suppresses aberrant autoimmune activation and alleviates autoimmune tissue injury, offering novel targets for non-hormonal therapy of autoimmune diseases.
In modulation of the tumor immune microenvironment, artesunate remodels the polarization phenotype of tumor-associated macrophages (TAMs). Within the tumor microenvironment, TAMs predominantly polarize toward the M2 phenotype, which promotes tumor proliferation, invasion and immune suppression, whereas M1 macrophages mediate anti-tumor immune surveillance.
Artesunate injection effectively drives TAM polarization from the pro-tumor M2 phenotype to the anti-tumor M1 phenotype, upregulates expression of M1 macrophage markers, strengthens immune cytotoxicity within the tumor microenvironment and hinders tumor immune escape. Meanwhile, the drug markedly inhibits PD-L1 expression in tumor cells, blocks the PD-1/PD-L1 immune checkpoint axis and reverses immune suppression in the tumor microenvironment. It activates anti-tumor immune activity of CD8+ T cells and NK cells, and exerts synergistic anti-tumor efficacy when combined with immune checkpoint inhibitors, presenting a new strategy for combinatorial tumor immunotherapy.
Mechanisms Regulating Multi-Organ Fibrosis Pathways
Organ fibrosis represents a shared pathological alteration in the end stage of diverse chronic diseases, characterized by aberrant fibroblast activation and excessive extracellular matrix deposition, ultimately leading to organ structural destruction and functional failure. Artesunate inhibits fibrotic progression by modulating two core fibrotic pathways: TGF-β/Smad and PI3K/Akt/mTOR, and demonstrates prominent anti-fibrotic activity in hepatic, renal, pulmonary, ocular and other organ fibrosis models.
The TGF-β/Smad pathway is the classical core cascade driving fibrogenesis. Abnormally elevated TGF-β triggers phosphorylation of downstream Smad proteins, facilitates fibroblast proliferation and activation, and induces massive synthesis and deposition of type I and type III collagen. Artesunate significantly downregulates TGF-β expression, suppresses phosphorylation of Smad2 and Smad3, obstructs nuclear translocation of Smad signals, and concurrently upregulates expression of the anti-fibrotic protein Smad7. It interrupts fibrotic signal transduction at the source, inhibits fibroblast activation and collagen deposition, and reverses early pathological changes of organ fibrosis.
The PI3K/Akt/mTOR pathway acts as a vital auxiliary cascade regulating cell proliferation and fibrotic remodeling. Abnormal activation of this pathway promotes fibroblast survival and proliferation and exacerbates extracellular matrix accumulation. Artesunate efficiently inhibits phosphorylation and activation of PI3K, Akt and mTOR proteins, blocks aberrant signal transmission of the pathway, restrains abnormal proliferation and activation of fibroblasts, and reduces deposition of matrix components such as collagen and fibronectin. Existing studies confirm that artesunate ameliorates pathological lesions in hepatic fibrosis, renal interstitial fibrosis and pulmonary fibrosis through the above dual pathways.
Moreover, it suppresses scar formation and preserves organ function in ocular fibrosis models including corneal fibrosis and retinal fibrosis, possessing broad-spectrum potential for anti-fibrotic applications.
Cutting-Edge Mechanisms of Direct Protein Targets (Recent Advances)
Previous studies generally presumed that the non-antimalarial effects of artesunate mainly rely on indirect ROS-mediated cellular stress responses, without well-defined direct molecular targets. This limitation hindered mechanistic elucidation and research on precise medication.
In recent years, with the application of precise molecular interaction technologies including CETSA, SPR and high-throughput proteomic screening, multiple direct binding protein targets of artesunate have been successfully identified. These findings break the traditional understanding of indirect effects, clarify the core mechanisms of its direct molecular interactions and advance pharmacological research toward precise molecular levels.
NEDD4L is one of the confirmed core direct targets of artesunate. As an E3 ubiquitin ligase, it participates in regulating multiple biological processes including cell proliferation, immunity and fibrosis.
Artesunate binds directly to NEDD4L, modulates its ubiquitination activity, thereby mediating degradation and functional remodeling of downstream target proteins, and participates in biological effects such as tumor suppression and immune regulation. SEC23A is another key direct target newly discovered in recent years. This protein is involved in cellular protein transport and secretion. Artesunate directly interacts with SEC23A to interfere with protein trafficking in tumor cells, suppress secretion of oncogenic proteins, and consequently arrest tumor cell proliferation and invasion.
Research and development of artemisinin originated from China's anti-malarial drug research initiative in the 1970s. Scientific teams extracted and isolated artemisinin, an anti-malarial active monomer, from the traditional Chinese herb Artemisia annua, overcoming the clinical challenge of drug resistance to anti-malarial agents at that time.
Nevertheless, natural artemisinin suffers from extremely poor water solubility, low bioavailability and limited administration routes, failing to meet clinical demands for emergency treatment of severe malaria. To optimize druggability, researchers conducted structural modification of artemisinin and synthesized artesunate, a semi-synthetic derivative with greatly improved water solubility via esterification reaction.Injectable formulations were successfully developed, completely resolving the barrier of intravenous administration for natural artemisinin.
In the 1980s, the product passed pharmacological, toxicological and clinical trial verification, confirming its advantages of potent, rapid anti-malarial efficacy and low toxicity, and was gradually introduced into clinical practice.
Subsequently validated by global multi-center clinical trials sponsored by the WHO, this drug was incorporated into global guidelines for severe malaria management and became a universally used core anti-malarial agent worldwide.
Over the past two decades, with deepening basic research, its non-antimalarial pharmacological activities have been continuously explored, enabling its transformation from a single-purpose anti-malarial wonder drug to a multi-indication candidate therapeutic agent.
FAQ
What is artesunate injection used for?
+
-
It is used to treat severe malaria. This medicine is also used together with other medicines (eg, 8-aminoquinoline medicine) to treat severe malaria caused by Plasmodium ovale or Plasmodium vivax. Asumax belongs to a group of medicines known as antimalarials.
How many days is an asumax injection given?
+
-
If, after the third IV asumax dose, the patient's parasite density is >1%, IV artesunate treatment should be continued with the recommended dose once a day for a maximum of seven days until parasite density is ≤1%. Doses given at 0, 12, and 24 hours count as one day, which means up to six additional days.
What are the side effects?
+
-
Check with your doctor right away if you or your child have back, leg, or stomach pains, bleeding gums, chills, dark urine, difficulty breathing, fever, general body swelling, headache, loss of appetite, nausea or vomiting, nosebleeds, pale skin, sore throat, unusual tiredness or weakness, or yellow eyes or skin.
Hot Tags: artesunate injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale